Synta Pharmaceuticals (SNTA) Sees IPO Pricing Between $14-16
More News related to SNTA
- Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com
- Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090
- Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
- Synta Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
- Synta Pharmaceuticals Reports Third Quarter 2009 Financial Results
In an amended S-1 filing with the SEC, Synta Pharmaceuticals (Nasdaq: SNTA) announced the pricing of its initial public offering of Common Stock between $14-$16 per share. The shares will begin trading today on the NASDAQ Global Market under the symbol "SNTA".
The offering will consist of 6,000,000 shares of Common Stock and made through an underwriting syndicate including Bear, Stearns & Co. Inc, Lazard Capital Markets, Lehman Brothers, and Montgomery & Co., LLC.
SNTA is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with large potential markets, including cancer and chronic inflammatory diseases.
Related Categories
IPOsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
